Literature DB >> 23908486

Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.

Myron J Levin1, Kenneth E Schmader, John W Gnann, Shelly A McNeil, Timo Vesikari, Robert F Betts, Susan Keay, Jon E Stek, Nickoya D Bundick, Shu-Chih Su, Yanli Zhao, Xiaoming Li, Ivan S F Chan, Paula W Annunziato, Janie Parrino.   

Abstract

Prevaccination and 6-week postvaccination samples from the immunogenicity substudy (n = 2269) of the zoster vaccine (ZV) efficacy trial (N = 22 439) in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to vaccination. The varicella-zoster virus geometric mean titer (GMT) and geometric mean fold rise were higher in ZV recipients than in placebo recipients (GMT, 660.0 vs 293.1 glycoprotein enzyme-linked immunosorbent assay units/mL [P < .001], respectively; geometric mean fold rise, 2.31 vs 1.00 [P < .025]). In each group there was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster. Although these data provide strong evidence that relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined. Clinical Trials Registration. NCT00534248.

Entities:  

Keywords:  herpes zoster; immunogenicity; zoster vaccine

Mesh：

Substances：

Year:  2013        PMID： 23908486      PMCID： PMC4550114          DOI： 10.1093/infdis/jit342

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  16 in total

1.  Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants.

Authors:  Atsuko Hata; Hideomi Asanuma; Mary Rinki; Margaret Sharp; Ruby M Wong; Karl Blume; Ann M Arvin
Journal:  N Engl J Med       Date:  2002-07-04       Impact factor: 91.245

2.  Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age.

Authors:  Clemente Diaz; Pietro Dentico; Rocio Gonzalez; Rafael G Mendez; Sandro Cinquetti; Julie L Barben; Anna Harmon; Ira Chalikonda; Jeffrey G Smith; Jon E Stek; Andrew Robertson; Michael J Caulfield; Luigi R Biasio; Jeffrey L Silber; Christina Y Chan; Rupert Vessey; Jerald Sadoff; Ivan S F Chan; Holly Matthews; William Wang; Katia Schlienger; Florian P Schödel
Journal:  Vaccine       Date:  2006-07-07       Impact factor: 3.641

3.  The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection.

Authors:  Olivia Hammond; Yue Wang; Tina Green; Joseph Antonello; Robert Kuhn; Clifford Motley; Philip Stump; Beverly Rich; Narendra Chirmule; Rocio D Marchese
Journal:  J Med Virol       Date:  2006-12       Impact factor: 2.327

4.  Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma.

Authors:  A M Arvin; R B Pollard; L E Rasmussen; T C Merigan
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

5.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Authors:  M N Oxman; M J Levin; G R Johnson; K E Schmader; S E Straus; L D Gelb; R D Arbeit; M S Simberkoff; A A Gershon; L E Davis; A Weinberg; K D Boardman; H M Williams; J Hongyuan Zhang; P N Peduzzi; C E Beisel; V A Morrison; J C Guatelli; P A Brooks; C A Kauffman; C T Pachucki; K M Neuzil; R F Betts; P F Wright; M R Griffin; P Brunell; N E Soto; A R Marques; S K Keay; R P Goodman; D J Cotton; J W Gnann; J Loutit; M Holodniy; W A Keitel; G E Crawford; S-S Yeh; Z Lobo; J F Toney; R N Greenberg; P M Keller; R Harbecke; A R Hayward; M R Irwin; T C Kyriakides; C Y Chan; I S F Chan; W W B Wang; P W Annunziato; J L Silber
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

6.  Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients.

Authors:  Masahiro Onozawa; Satoshi Hashino; Mutsumi Takahata; Fumie Fujisawa; Takahito Kawamura; Masao Nakagawa; Kaoru Kahata; Takeshi Kondo; Shuichi Ota; Junji Tanaka; Masahiro Imamura; Masahiro Asaka
Journal:  J Clin Microbiol       Date:  2006-10-11       Impact factor: 5.948

7.  Racial differences in the occurrence of herpes zoster.

Authors:  K Schmader; L K George; B M Burchett; C F Pieper; J D Hamilton
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

8.  Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Rafael Harpaz; Ismael R Ortega-Sanchez; Jane F Seward
Journal:  MMWR Recomm Rep       Date:  2008-06-06

9.  Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.

Authors:  M J Levin; M N Oxman; J H Zhang; G R Johnson; H Stanley; A R Hayward; M J Caulfield; M R Irwin; J G Smith; J Clair; I S F Chan; H Williams; R Harbecke; R Marchese; S E Straus; A Gershon; A Weinberg
Journal:  J Infect Dis       Date:  2008-03-15       Impact factor: 5.226

10.  Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay.

Authors:  Kay Sadaoka; Shigefumi Okamoto; Yasuyuki Gomi; Takeshi Tanimoto; Toyokazu Ishikawa; Tetsushi Yoshikawa; Yoshizo Asano; Koichi Yamanishi; Yasuko Mori
Journal:  J Infect Dis       Date:  2008-11-01       Impact factor: 5.226
View more
  17 in total

1.  Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine.

Authors:  Michael N Oxman; Ruth Harbecke; David M Koelle
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226

2.  Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.

Authors:  Constance A Benson; Janet W Andersen; Bernard J C Macatangay; Robbie B Mailliard; Charles R Rinaldo; Sarah Read; Dawn R Bozzolo; Lynette Purdue; Cheryl Jennings; Michael C Keefer; Marshall Glesby; Pablo Tebas; Amy Falk Russell; Jason Martin; Paula Annunziato; Zoran Popmihajlov; Jeffrey L Lennox
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

Review 3.  Vaccination for quality of life: herpes-zoster vaccines.

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Aging Clin Exp Res       Date:  2019-10-23       Impact factor: 3.636

4.  High Constitutive Interleukin 10 Level Interferes With the Immune Response to Varicella-Zoster Virus in Elderly Recipients of Live Attenuated Zoster Vaccine.

Authors:  Anne A Gershon; David Brooks; Donald D Stevenson; William K Chin; Michael B A Oldstone; Michael D Gershon
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

5.  Low Rates of Vaccination for Herpes Zoster in Older People Living With HIV.

Authors:  Kristine M Erlandson; Amber Streifel; Alexander R Novin; Kellie L Hawkins; Clayton Foster; Jacob Langness; Mary Bessesen; Julian Falutz; Abeer Moanna; David Looney; Scott T Johns; Joseph B Nguyen; Michael N Oxman; Myron J Levin
Journal:  AIDS Res Hum Retroviruses       Date:  2018-05-21       Impact factor: 2.205

Review 6.  Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?

Authors:  Anne A Gershon
Journal:  J Infect       Date:  2017-06       Impact factor: 6.072

Review 7.  Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults.

Authors:  Catherine Amlie-Lefond; Don Gilden
Journal:  J Stroke Cerebrovasc Dis       Date:  2016-04-29       Impact factor: 2.136

8.  Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.

Authors:  Benson Ogunjimi; Evelien Smits; Steven Heynderickx; Johan Van den Bergh; Joke Bilcke; Hilde Jansens; Ronald Malfait; Jose Ramet; Holden T Maecker; Nathalie Cools; Philippe Beutels; Pierre Van Damme
Journal:  Clin Vaccine Immunol       Date:  2014-01-15

9.  Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.

Authors:  Peter B Gilbert; Erin E Gabriel; Xiaopeng Miao; Xiaoming Li; Shu-Chih Su; Janie Parrino; Ivan S F Chan
Journal:  J Infect Dis       Date:  2014-05-13       Impact factor: 5.226

10.  Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.

Authors:  Kerry J Laing; Ronnie M Russell; Lichun Dong; D Scott Schmid; Michael Stern; Amalia Magaret; Jürgen G Haas; Christine Johnston; Anna Wald; David M Koelle
Journal:  J Infect Dis       Date:  2015-03-17       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.